Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pelrinone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.70 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.70 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 0.70 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.70 |
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.40 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.40 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pelrinone SCHEMBL783978 | 0.99 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL7289643 | 0.87 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| Hydrochloric Acid SCHEMBL7288081 | 0.87 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL10813332 | 0.87 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| Hydrochloric Acid SCHEMBL7281579 | 0.86 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL7289958 | 0.86 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL7289446 | 0.85 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| Hydrochloric Acid SCHEMBL7292375 | 0.85 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL7291924 | 0.85 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL7281876 | 0.85 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 542 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161298-A1 | METHODS OF TREATING, AMELIORATING, OR PREVENTING HEART FAILURE, AND METHODS OF PROMOTING HEART MUSCLE GROWTH | UNIV YALE (US) | 2025-05-22 | — | — | US | claimed |
| WO-2023164452-A2 | METHODS OF TREATING, AMELIORATING, OR PREVENTING HEART FAILURE, AND METHODS OF PROMOTING HEART MUSCLE GROWTH | YALE UNIVERSITY (US) | 2023-08-31 | — | — | WO | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20260144935-A1 | DRIVE ASSEMBLY FOR A DRUG DELIVERY DEVICE AND RELATED METHODS | AMGEN INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4240450-B1 | DRUG DELIVERY DEVICE ASSEMBLY AND ACCESSORY FOR DRUG DELIVERY DEVICE | AMGEN INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260124394-A1 | DRUG DELIVERY DEVICES, COMPONENTS FOR USE WITHIN DRUG DELIVERY DEVICES, AND METHODS OF OPERATING DRUG DELIVERY DEVICES | AMGEN INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12618859-B2 | Methods and systems for automated syringe quality evaluation | AMGEN INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12616795-B2 | Drug delivery device and methods of delivering a drug | AMGEN INC. (US) | 2026-05-05 | — | — | US | disclosed |
| WO-2026090381-A1 | DRUG DELIVERY DEVICE AND RELATED METHODS | AMGEN INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-0445190-B1 | PHARMACEUTICAL PRODUCT HAVING, IN PARTICULAR, A CARDIAC TROPISM COMPRISING A NITRURO COMPLEX OF A TRANSITION METAL AND PROCESS FOR PREPARATION THEREOF | CIS BIO INTERNATIONAL (FR) | 1993-09-15 | — | — | EP | disclosed |
| EP-0320805-B1 | ACYLATED BENZILIC ACID DERIVATIVES FOR THE REGULATION OF THE TONUS OF THE URINARY BLADDER | SCHAPER & BRÜMMER GMBH & CO. KG (DE) | 1992-03-04 | — | — | EP | disclosed |
| EP-0445190-A1 | PHARMACEUTICAL PRODUCT HAVING, IN PARTICULAR, A CARDIAC TROPISM COMPRISING A NITRURO COMPLEX OF A TRANSITION METAL AND PROCESS FOR PREPARATION THEREOF. | CIS BIO INT (FR) | 1991-09-11 | — | — | EP | disclosed |
| WO-1990006137-A1 | PHARMACEUTICAL PRODUCT HAVING, IN PARTICULAR, A CARDIAC TROPISM COMPRISING A NITRURO COMPLEX OF A TRANSITION METAL AND PROCESS FOR PREPARATION THEREOF | CIS BIO INTERNATIONAL (FR) | 1990-06-14 | — | — | WO | disclosed |
| EP-0364584-A1 | ANTIDOTE FOR ORGANIC PHOSPHORUS COMPOUND POISONING | KIEVSKY NAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII I TOXIKOLOGII (SU) | 1990-04-25 | — | — | EP | disclosed |
| EP-0342474-A2 | Use of diazepinones for the preparation of a medicament for therapy of microcirculatory disorders | Dr. Karl Thomae GmbH (DE) | 1989-11-23 | — | — | EP | disclosed |
| EP-0320805-A2 | Acylated benzilic acid derivatives for the regulation of the tonus of the urinary bladder | SCHAPER & BRÜMMER GMBH & CO. KG (DE) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616795-B2 | Drug delivery device and methods of delivering a drug | ABCC1, USE1, CRH | PDE4A 960/4885PDE4B 1027/4885PDE4C 591/4885 |
| US-20260124394-A1 | DRUG DELIVERY DEVICES, COMPONENTS FOR USE WITHIN DRUG DELIVERY DEVICES, AND METHODS OF OPERATING DRUG DELIVERY DEVICES | PER2, CRY1, CRH | PDE4A 421/4885PDE4B 286/4885PDE4C 575/4885 |
| US-12618859-B2 | Methods and systems for automated syringe quality evaluation | EIF2A, EIF3D, SRPRA | PDE4A 2124/4885PDE4B 2889/4885PDE4C 2235/4885 |
| US-20260144935-A1 | DRIVE ASSEMBLY FOR A DRUG DELIVERY DEVICE AND RELATED METHODS | CRH, PDE1C, DYNLL2 | PDE4A 728/4885PDE4B 836/4885PDE4C 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.